Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On March 31, 2026, Imunon, Inc. (IMNN) announced financial results for the fourth quarter and full year 2025 and provided a business update.</li><li>The company announced that the Phase 3 OVATION 3 trial remains ahead of plan, supported by the strong interest from principal investigators and patients in an indication that has not seen appreciable advancements in frontline standard of care for over 30 years.</li><li>Imunon also recently highlighted the final data assessment from the Phase 2 OVATION 2 trial that showed treatment with IMNN-001 was associated with an overall survival benefit of more than a year and more than two years for patients also receiving PARP inhibitors as maintenance therapy.</li></ul>

On March 31, 2026, Imunon, Inc. (IMNN) announced financial results for the fourth quarter and full year 2025 and provided a business update.The company announced that the Phase 3 OVATION 3 trial remains ahead of plan, supported by the strong interest from principal investigators and patients in an indication that has not seen appreciable advancements in frontline standard of care for over 30 years.Imunon also recently highlighted the final data assessment from the Phase 2 OVATION 2 trial that showed treatment with IMNN-001 was associated with an overall survival benefit of more than a year and more than two years for patients also receiving PARP inhibitors as maintenance therapy.

IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule

<ul><li>On March 25, 2026, Imunon, Inc. (IMNN) announced updated overall survival (OS) data from the OVATION 2 trial that showed a now 14.7-month increase in OS (45.1 vs. 30.4 months) for women receiving IMNN-001 along with standard of care (SoC) chemotherapy compared to SoC alone.</li><li>In addition, women treated with IMNN-001 and SoC along with poly ADP-ribose polymerase (PARP) inhibitors achieved a median increase in OS of 24.2 months (65.6 vs. 41.4 months) compared to SoC alone.</li><li>The continued increase in OS shows that IMNN-001 is having a meaningful impact in the treatment of ovarian cancer patients, which is particularly important given that there have been no meaningful advances in SoC for ovarian cancer in the past 30 years.</li></ul>

On March 25, 2026, Imunon, Inc. (IMNN) announced updated overall survival (OS) data from the OVATION 2 trial that showed a now 14.7-month increase in OS (45.1 vs. 30.4 months) for women receiving IMNN-001 along with standard of care (SoC) chemotherapy compared to SoC alone.In addition, women treated with IMNN-001 and SoC along with poly ADP-ribose polymerase (PARP) inhibitors achieved a median increase in OS of 24.2 months (65.6 vs. 41.4 months) compared to SoC alone.The continued increase in OS shows that IMNN-001 is having a meaningful impact in the treatment of ovarian cancer patients, which is particularly important given that there have been no meaningful advances in SoC for ovarian cancer in the past 30 years.

IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC

<ul><li>Imunon, Inc. (IMNN) has its full attention on the successful execution of the Phase 3 OVATION 3 trial, which is evaluating IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer.</li><li> The company recently announced a strategic restructuring to align its resources to rapidly advance the OVATION 3 trial, which includes the retirement of Chief Scientific Officer Dr. Khursheed Anwer and the redefining of job descriptions for additional employees to reduce operating expenses.</li><li>Imunon is currently evaluating different funding options and in the near-term will likely employ one or two additional bridge financings like the recently completed $7.0 million registered direct offering as a means to ensure uninterrupted continuation of the OVATION 3 trial until long-term financing is secured.</li></ul>

Imunon, Inc. (IMNN) has its full attention on the successful execution of the Phase 3 OVATION 3 trial, which is evaluating IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. The company recently announced a strategic restructuring to align its resources to rapidly advance the OVATION 3 trial, which includes the retirement of Chief Scientific Officer Dr. Khursheed Anwer and the redefining of job descriptions for additional employees to reduce operating expenses.Imunon is currently evaluating different funding options and in the near-term will likely employ one or two additional bridge financings like the recently completed $7.0 million registered direct offering as a means to ensure uninterrupted continuation of the OVATION 3 trial until long-term financing is secured.

IMNN: Streamlining Operations to Focus on OVATION 3

<ul><li>On November 10, 2025, Imunon, Inc. (IMNN) held an R&D Day and provided updates on the latest data for IMNN-001 along with the ongoing OVATION 3 trial.</li><li>Multiple speakers at the event highlighted the ability of IMNN-001 to turn "cold" tumors "hot", its highly favorable benefit/risk profile, new translational data showing how IMNN-001 is taken up by macrophages in the peritoneal fluid that leads to a robust immune response, along with the statistical plan for the OVATION 3 trial.</li><li>The company also recently presented at the SITC 40th Annual Meeting where new translational data from the OVATION 2 study demonstrated how IMNN-001 can remodel the tumor microenvironment through increased recruitment of CD8+ T cells.</li></ul>

On November 10, 2025, Imunon, Inc. (IMNN) held an R&D Day and provided updates on the latest data for IMNN-001 along with the ongoing OVATION 3 trial.Multiple speakers at the event highlighted the ability of IMNN-001 to turn "cold" tumors "hot", its highly favorable benefit/risk profile, new translational data showing how IMNN-001 is taken up by macrophages in the peritoneal fluid that leads to a robust immune response, along with the statistical plan for the OVATION 3 trial.The company also recently presented at the SITC 40th Annual Meeting where new translational data from the OVATION 2 study demonstrated how IMNN-001 can remodel the tumor microenvironment through increased recruitment of CD8+ T cells.

IMNN: R&D Day Highlights Potential for IMNN-001 

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, ADAP received the first TCR-T cell therapy approval in solid tumors. SNDX hit a minor regulatory speed bump, while VTVT got a clinical hold.</li><li>VTYX will move past Tyk2 after its Crohn’s failure. LLY succeeded in its heart failure trial with an obesity drug. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, ADAP received the first TCR-T cell therapy approval in solid tumors. SNDX hit a minor regulatory speed bump, while VTVT got a clinical hold.VTYX will move past Tyk2 after its Crohn’s failure. LLY succeeded in its heart failure trial with an obesity drug. 

United States

IMUNON, Inc. operates as a clinical stage biotechnology company. The Company focuses on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Imunon (IMNN US)

IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule

On March 31, 2026, Imunon, Inc. (IMNN) announced financial results for the fourth quarter and full year 2025 and provided a business update. The...

Zacks Small Cap Research

IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC

On March 25, 2026, Imunon, Inc. (IMNN) announced updated overall survival (OS) data from the OVATION 2 trial that showed a now 14.7-month increase...

Zacks Small Cap Research

IMNN: Streamlining Operations to Focus on OVATION 3

Imunon, Inc. (IMNN) has its full attention on the successful execution of the Phase 3 OVATION 3 trial, which is evaluating IMNN-001 in combination...

Zacks Small Cap Research

IMNN: R&D Day Highlights Potential for IMNN-001

On November 10, 2025, Imunon, Inc. (IMNN) held an R&D Day and provided updates on the latest data for IMNN-001 along with the ongoing OVATION...

Zacks Small Cap Research

Biopharma Week in Review

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)